OpenLB
Open Library of Bioscience

Exploring the frontier of cardiovascular pharmacotherapy.

Abstract

No abstract text available.

References

1. Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143:e254-e743. doi:10.1161/CIR.0000000000000950
2. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596-e646. doi:10.1161/CIR.0000000000000678
3. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749-1767.
4. Talasaz AH, Ho A, Bhatty F, et al. Meta-analysis of clinical outcomes of PCSK9 Modulators in patients with established ASCVD. Pharmacotherapy. 2021;12:1009-1023.
5. Barry A, Dixon D. Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease. Pharmacotherapy. 2021;12:1056-1065.
6. An J, Fang N, Sim J. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease. Pharmacotherapy. 2021;12:998-1008.
7. Sud M, Ko DT, Chong A, et al. Renin-angiotensin-aldosterone system inhibitors and major cardiovascular and acute kidney injury in patients with coronary artery disease. Pharmacotherapy. 2021;12:988-997.
8. Wood B, Lee CR, Mulrenin IR, et al. Effects of aging on clinical outcomes in patients receiving genotype-guided P2Y12 inhibitor selection after percutaneous coronary intervention. Pharmacotherapy. 2021;12:970-977.
9. Veeder J, Hothem LN, Cipriani AE, et al. Chemotherapy-associated cardiomyopathy: mechanisms of toxicity and cardioprotective strategies. Pharmacotherapy. 2021;12:1066-1080.
10. Warner AL. Advances in the treatment of transthyretin cardiac amyloidosis: current and emerging therapies. Pharmacotherapy. 2021;12:1081-1091.
11. Demeny L, Vardeny O, Edelmann F, et al. NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial. Pharmacotherapy. 2021;12:978-987.
12. Jennings DL, Gadela NV, Jaiswal A, et al. Pre-transplant amiodarone use does not affect long-term heart transplant survival. Pharmacotherapy. 2021;12:1024-1032.
13. Stewart JJ, Turgeon R, Parker A, et al. Comparison of risk-scoring systems for heparin-induced thrombocytopenia in cardiac surgery patients. Pharmacotherapy. 2021;12:1033-1040.
14. Schwier NC, Tsui J, Perrine JA, et al. Current pharmacotherapy management of children and adults with pericarditis: prospectus for improved outcomes. Pharmacotherapy. 2021;12:1041-1055.

MeSH Term